Bernard H Bochner

List of Publications by Year
in descending order

240	26,499	12330 69	6471 157
papers	citations	h-index	g-index

255	255	255	23264
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients. Journal of Clinical Oncology, 2001, 19, 666-675.	1.6	3,157
2	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
3	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
4	Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology. European Urology, 2009, 55, 164-176.	1.9	1,145
5	Genome Sequencing Identifies a Basis for Everolimus Sensitivity. Science, 2012, 338, 221-221.	12.6	681
6	Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. Journal of Urology, 2017, 198, 552-559.	0.4	632
7	IMPACT OF THE NUMBER OF LYMPH NODES RETRIEVED ON OUTCOME IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. Journal of Urology, 2002, 167, 1295-1298.	0.4	544
8	The mechanism of action of BCG therapy for bladder cancerâ€"a current perspective. Nature Reviews Urology, 2014, 11, 153-162.	3.8	535
9	Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. Cancer Discovery, 2014, 4, 1140-1153.	9.4	506
10	Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. European Urology, 2015, 67, 1042-1050.	1.9	453
11	Postoperative Nomogram Predicting Risk of Recurrence After Radical Cystectomy for Bladder Cancer. Journal of Clinical Oncology, 2006, 24, 3967-3972.	1.6	419
12	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.9	372
13	Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer, 2006, 107, 506-513.	4.1	360
14	Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer. Journal of Clinical Oncology, 2013, 31, 3133-3140.	1.6	282
15	Ageâ€adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer, 2008, 112, 2384-2392.	4.1	281
16	The effect of age and gender on bladder cancer: a critical review of the literature. BJU International, 2010, 105, 300-308.	2.5	281
17	Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU International, 2014, 113, 11-23.	2.5	274
18	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. European Urology, 2017, 72, 952-959.	1.9	263

#	Article	IF	Citations
19	A role for neoadjuvant gemcitabine plus cisplatin in muscleâ€invasive urothelial carcinoma of the bladder. Cancer, 2008, 113, 2471-2477.	4.1	239
20	IMPACT OF SEPARATE VERSUS EN BLOC PELVIC LYMPH NODE DISSECTION ON THE NUMBER OF LYMPH NODES RETRIEVED IN CYSTECTOMY SPECIMENS. Journal of Urology, 2001, 166, 2295-2296.	0.4	232
21	Enhanced Recovery after Urological Surgery: A Contemporary Systematic Review of Outcomes, Key Elements, and Research Needs. European Urology, 2016, 70, 176-187.	1.9	230
22	Potential Impact of Postoperative Early Complications on the Timing of Adjuvant Chemotherapy in Patients Undergoing Radical Cystectomy: A High-Volume Tertiary Cancer Center Experience. European Urology, 2009, 55, 177-186.	1.9	227
23	Changes in Renal Function Following Nephroureterectomy May Affect the Use of Perioperative Chemotherapy. European Urology, 2010, 58, 581-587.	1.9	227
24	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research, 2017, 23, 3610-3618.	7.0	225
25	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
26	Standardization of pelvic lymphadenectomy performed at radical cystectomy. Cancer, 2006, 107, 2368-2374.	4.1	215
27	A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology, 2012, 62, 523-533.	1.9	214
28	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. European Urology, 2015, 68, 238-253.	1.9	211
29	International Validation of a Preoperative Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy. Journal of Clinical Oncology, 2002, 20, 3206-3212.	1.6	203
30	Detection of Methylated Apoptosis-Associated Genes in Urine Sediments of Bladder Cancer Patients. Clinical Cancer Research, 2004, 10, 7457-7465.	7.0	202
31	Genomic Characterization of Upper Tract Urothelial Carcinoma. European Urology, 2015, 68, 970-977.	1.9	202
32	PROSPECTIVELY PACKAGED LYMPH NODE DISSECTIONS WITH RADICAL CYSTECTOMY: EVALUATION OF NODE COUNT VARIABILITY AND NODE MAPPING. Journal of Urology, 2004, 172, 1286-1290.	0.4	193
33	Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. European Urology, 2018, 74, 465-471.	1.9	189
34	Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer. Clinical Cancer Research, 2012, 18, 1323-1333.	7.0	177
35	Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscleâ€invasive and nonâ€organ confined disease in patients with upper tract urothelial carcinoma. BJU International, 2012, 109, 77-82.	2.5	164
36	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clinical Cancer Research, 2019, 25, 967-976.	7.0	164

#	Article	IF	Citations
37	Phase II Trial of Intravesical Gemcitabine in Bacille Calmette-GuÃ©rinâ€“Refractory Transitional Cell Carcinoma of the Bladder. Journal of Clinical Oncology, 2006, 24, 2729-2734.	1.6	160
38	The Effect of Tumor Location on Prognosis in Patients Treated with Radical Nephroureterectomy at Memorial Sloan-Kettering Cancer Center. European Urology, 2010, 58, 574-580.	1.9	159
39	Best Practices in Robot-assisted Radical Cystectomy and Urinary Reconstruction: Recommendations of the Pasadena Consensus Panel. European Urology, 2015, 67, 363-375.	1.9	158
40	PARTIAL CYSTECTOMY: A CONTEMPORARY REVIEW OF THE MEMORIAL SLOAN-KETTERING CANCER CENTER EXPERIENCE AND RECOMMENDATIONS FOR PATIENT SELECTION. Journal of Urology, 2004, 172, 878-881.	0.4	151
41	Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecologic Oncology, 2005, 99, 608-614.	1.4	148
42	Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer. Journal of Urology, 2007, 177, 1283-1286.	0.4	146
43	The Role of Laparoscopic and Robotic Cystectomy in the Management of Muscle-Invasive Bladder Cancer With Special Emphasis on Cancer Control and Complications. European Urology, 2011, 60, 767-775.	1.9	145
44	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nature Genetics, 2016, 48, 356-358.	21.4	143
45	Urachal Carcinoma: Contemporary Surgical Outcomes. Journal of Urology, 2007, 178, 74-78.	0.4	137
46	THE T POUCH: AN ORTHOTOPIC ILEAL NEOBLADDER INCORPORATING A SEROSAL LINED ILEAL ANTIREFLUX TECHNIQUE. Journal of Urology, 1998, 159, 1836-1842.	0.4	133
47	Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. Journal of Urology, 2002, 167, 1295-8.	0.4	133
48	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€”An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	1.9	132
49	Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. European Urology, 2015, 67, 198-201.	1.9	122
50	A Randomized Trial of Robot-Assisted Laparoscopic Radical Cystectomy. New England Journal of Medicine, 2014, 371, 389-390.	27.0	114
51	Synthetic Lethality in ATM-Deficient RAD50-Mutant Tumors Underlies Outlier Response to Cancer Therapy. Cancer Discovery, 2014, 4, 1014-1021.	9.4	114
52	Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1 Bladder Cancer. European Urology, 2009, 56, 903-910.	1.9	111
53	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 2018, 36, 1949-1956.	1.6	110
54	Genomic Differences Between â€œPrimaryâ€•and â€œSecondaryâ€•Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. European Urology, 2019, 75, 231-239.	1.9	104

#	Article	IF	Citations
55	Comparison Between Laparoscopic and Open Radical Nephroureterectomy in a Contemporary Group of Patients: Are Recurrence and Disease-Specific Survival Associated with Surgical Technique?. European Urology, 2010, 58, 645-651.	1.9	98
56	Lymph Nodeâ€“Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity. European Urology, 2012, 61, 1025-1030.	1.9	98
57	Orthotopic Urinary Diversion After Cystectomy For Bladder Cancer: Implications For Cancer Control And Patterns Of Disease Recurrence. Journal of Urology, 2003, 169, 177-181.	0.4	97
58	Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2020, 3, 306-315.	5.4	97
59	Risk Assessment of Prostatic Pathology in Patients Undergoing Radical Cystoprostatectomy. European Urology, 2008, 53, 370-375.	1.9	90
60	BLADDER CANCER AS A PROGNOSTIC FACTOR FOR UPPER TRACT TRANSITIONAL CELL CARCINOMA. Journal of Urology, 2004, 172, 2177-2181.	0.4	89
61	SALVAGE RADICAL CYSTOPROSTATECTOMY AND ORTHOTOPIC URINARY DIVERSION FOLLOWING RADIATION FAILURE. Journal of Urology, 1998, 160, 29-33.	0.4	88
62	Superficial and Muscle-Invasive Bladder Cancer: Principles of Management for Outcomes Assessments. Journal of Clinical Oncology, 2006, 24, 5519-5527.	1.6	88
63	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical Cancer Research, 2018, 24, 1965-1973.	7.0	85
64	Prospective Trial of Ifosfamide, Paclitaxel, and Cisplatin in Patients with Advanced Non-transitional Cell Carcinoma of the Urothelial Tract. Urology, 2007, 69, 255-259.	1.0	79
65	Pathological response to neoadjuvant chemotherapy for muscleâ€invasive micropapillary bladder cancer. BJU International, 2013, 111, E325-30.	2.5	78
66	Risk Factors for the Development of Parastomal Hernia after Radical Cystectomy. Journal of Urology, 2014, 191, 1708-1713.	0.4	76
67	Oncological Outcomes After Radical Cystectomy for Bladder Cancer: Open Versus Minimally Invasive Approaches. Journal of Urology, 2010, 183, 862-870.	0.4	74
68	Longitudinal Risk of Upper Tract Recurrence Following Radical Cystectomy for Urothelial Cancer and the Potential Implications for Long-Term Surveillance. Journal of Urology, 2008, 179, 96-100.	0.4	73
69	Somatic mutation of fibroblast growth factor receptorâ€3 (FGFR3) defines a distinct morphological subtype of highâ€grade urothelial carcinoma. Journal of Pathology, 2011, 224, 270-279.	4.5	73
70	Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. European Urology, 2017, 71, 545-557.	1.9	72
71	Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer. Cancer, 2006, 107, 2167-2172.	4.1	69
72	Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nature Reviews Urology, 2014, 11, 589-596.	3.8	69

#	Article	IF	Citations
73	Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecologic Oncology, 2012, 124, 42-47.	1.4	63
74	Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma. Clinical Cancer Research, 2014, 20, 1873-1883.	7.0	63
75	DOES BODY MASS INDEX AFFECT SURVIVAL OF PATIENTS UNDERGOING RADICAL OR PARTIAL CYSTECTOMY FOR BLADDER CANCER?. Journal of Urology, 2005, 173, 1513-1517.	0.4	62
76	Lymphadenectomy for Bladder Cancer at the Time of Radical Cystectomy. European Urology, 2013, 64, 266-276.	1.9	62
77	Follow-up strategies and management of recurrence in urologic oncology bladder cancer:. Urologic Clinics of North America, 2003, 30, 777-789.	1.8	61
78	Clinical Outcome of Patients with T1 Micropapillary Urothelial Carcinoma of the Bladder. Journal of Urology, 2014, 192, 702-707.	0.4	61
79	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. Journal of Clinical Oncology, 2020, 38, 406-414.	1.6	60
80	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology. American Journal of Surgical Pathology, 2019, 43, 920-927.	3.7	59
81	Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Therapy, 2001, 8, 879-889.	4.6	58
82	The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy. European Urology Focus, 2019, 5, 104-108.	3.1	58
83	Evaluation of regional lymph node dissection in patients with upper urinary tract urothelial cancer. International Journal of Urology, 2007, 14, 26-32.	1.0	57
84	Bladder Cancer: Narrowing the Gap Between Evidence and Practice. Journal of Clinical Oncology, 2009, 27, 5680-5684.	1.6	56
85	Pubovesical Fistula: A Rare Complication After Treatment of Prostate Cancer. Urology, 2012, 80, 446-451.	1.0	53
86	Safety and Efficacy of Intravesical Bacillus Calmette-Guerin Instillations in Steroid Treated and Immunocompromised Patients. Journal of Urology, 2006, 176, 482-485.	0.4	52
87	A Critical Analysis of Orthotopic Bladder Substitutes in Adult Patients with Bladder Cancer: Is There a Perfect Solution?. European Urology, 2010, 58, 374-383.	1.9	52
88	A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. Urology, 2017, 102, 164-172.	1.0	52
89	Tissue-Specific Transcriptional Targeting of a Replication-Competent Retroviral Vector. Journal of Virology, 2002, 76, 12783-12791.	3.4	51
90	Initial Results with 11C-Acetate Positron Emission Tomography/Computed Tomography (PET/CT) in the Staging of Urinary Bladder Cancer. Molecular Imaging and Biology, 2012, 14, 245-251.	2.6	51

#	Article	IF	Citations
91	Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer, 2016, 122, 3715-3723.	4.1	50
92	Clinical Outcomes of Primary Bladder Carcinoma In Situ in a Contemporary Series. Journal of Urology, 2010, 184, 74-80.	0.4	48
93	Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. BJU International, 2006, 98, 59-62.	2.5	47
94	Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046).. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 637-644.	1.6	46
95	A prospective study of quality of life in patients undergoing pelvic exenteration: Interim results. Gynecologic Oncology, 2013, 128, 191-197.	1.4	44
96	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. Journal of Clinical Oncology, 2022, 40, 1312-1322.	1.6	42
97	A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor. Journal of Urology, 2016, 196, 1014-1020.	0.4	41
98	Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-GuÃ©rin Treatment Failure. Journal of Urology, 2013, 190, 1686-1691.	0.4	40
99	Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice, 2017, 13, 621-625.	2.5	40
100	Upper Tract Imaging Surveillance is not Effective in Diagnosing Upper Tract Recurrence in Patients Followed for Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2013, 190, 1187-1191.	0.4	38
101	Perceptions of Response Burden Associated with Completion of Patient-Reported Outcome Assessments in Oncology. Value in Health, 2019, 22, 225-230.	0.3	38
102	Risk of Fracture After Radical Cystectomy and Urinary Diversion for Bladder Cancer. Journal of Clinical Oncology, 2014, 32, 3291-3298.	1.6	37
103	Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. Journal of Pathology, 2019, 248, 260-265.	4.5	37
104	A Population-based Study of Ureteroenteric Strictures After Open and Robot-assisted Radical Cystectomy. Urology, 2020, 135, 57-65.	1.0	37
105	Bladder cancer: can imaging change patient management?. Current Opinion in Urology, 2008, 18, 98-104.	1.8	36
106	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. Journal of Urology, 2016, 195, 1684-1689.	0.4	36
107	Clinical Outcome of Primary Versus Secondary Bladder Carcinoma In Situ. Journal of Urology, 2010, 184, 464-469.	0.4	35
108	Who should be included in a clinical trial of screening for bladder cancer?. Cancer, 2013, 119, 143-149.	4.1	35

#	Article	IF	Citations
109	Leveraging Latent Dirichlet Allocation in processing free-text personal goals among patients undergoing bladder cancer surgery. Quality of Life Research, 2019, 28, 1441-1455.	3.1	34
110	Prognostic significance of p27Kip1expression in bladder cancer. BJU International, 2007, 100, 259-263.	2.5	33
111	Parastomal hernias after radical cystectomy and ileal conduit diversion. Investigative and Clinical Urology, 2016, 57, 240.	2.0	33
112	Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort. European Urology, 2022, 81, 294-304.	1.9	33
113	Detection and Quantitative Analysis of Early Stage Orthotopic Murine Bladder Tumor Using In Vivo Magnetic Resonance Imaging. Journal of Urology, 2003, 170, 1375-1378.	0.4	32
114	Inhibition of Orthotopic Human Bladder Tumor Growth by Lentiviral Gene Transfer of Endostatin. Clinical Cancer Research, 2004, 10, 1835-1842.	7.0	32
115	Clinical benefits of a multivariate prediction model for bladder cancer. Cancer, 2009, 115, 5460-5469.	4.1	32
116	Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. Clinical Genitourinary Cancer, 2020, 18, 387-394.	1.9	32
117	Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings. International Urology and Nephrology, 2014, 46, 1699-1705.	1.4	31
118	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World Journal of Urology, 2019, 37, 51-60.	2.2	31
119	HERPES SIMPLEX VIRUS BASED GENE THERAPY ENHANCES THE EFFICACY OF MITOMYCIN C FOR THE TREATMENT OF HUMAN BLADDER TRANSITIONAL CELL CARCINOMA. Journal of Urology, 2005, 174, 741-746.	0.4	30
120	Genomic and Proteomic Profiles Reveal the Association of Gelsolin to TP53 Status and Bladder Cancer Progression. American Journal of Pathology, 2007, 171, 1650-1658.	3.8	30
121	Cost Comparison of Open and Robotic Partial Nephrectomy Using a Short Postoperative Pathway. Urology, 2015, 85, 596-604.	1.0	30
122	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. European Urology Focus, 2019, 5, 201-204.	3.1	30
123	Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. European Urology, 2020, 77, 669-670.	1.9	30
124	Highly Efficient Gene Delivery for Bladder Cancers by Intravesically Administered Replication-Competent Retroviral Vectors. Clinical Cancer Research, 2007, 13, 4511-4518.	7.0	29
125	Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. JCO Precision Oncology, 2018, 2018, 1-13.	3.0	29
126	Rationale and Early Experience with Prophylactic Placement of Mesh to Prevent Parastomal Hernia Formation after Ileal Conduit Urinary Diversion and Cystectomy for Bladder Cancer. Current Urology Reports, 2016, 17, 9.	2.2	28

#	Article	IF	Citations
127	Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. Journal of Urology, 2003, 169, 177-81.	0.4	28
128	The psychological context of quality of life: a psychometric analysis of a novel idiographic measure of bladder cancer patients' personal goals and concerns prior to surgery. Health and Quality of Life Outcomes, 2011, 9, 10.	2.4	27
129	Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Human Pathology, 2018, 77, 63-69.	2.0	27
130	Impact of Previous Radiotherapy for Prostate Cancer on Clinical Outcomes of Patients With Bladder Cancer. Journal of Urology, 2010, 183, 1751-1756.	0.4	26
131	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World Journal of Urology, 2017, 35, 327-335.	2.2	26
132	Nextâ€generation sequencing of urine specimens: A novel platform for genomic analysis in patients with nonâ€“muscleâ€invasive urothelial carcinoma treated with bacille Calmetteâ€GuÃ©rin. Cancer Cytopathology, 2017, 125, 416-426.	2.4	26
133	Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-GuÃ©rin Immunotherapy in Nonâ€“Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2021, 27, 4599-4609.	7.0	26
134	Natural History of Positive Urinary Cytology After Radical Cystectomy. Journal of Urology, 2006, 176, 2000-2005.	0.4	25
135	Comparison of Perioperative Outcomes for Epidural Versus Intravenous Patient-Controlled Analgesia After Radical Cystectomy. Regional Anesthesia and Pain Medicine, 2015, 40, 239-244.	2.3	25
136	Ileal conduit or orthotopic neobladder: selection and contemporary patterns of use. Current Opinion in Urology, 2020, 30, 415-420.	1.8	25
137	Goal-directed versus Standard Fluid Therapy to Decrease Ileus after Open Radical Cystectomy. Anesthesiology, 2020, 133, 293-303.	2.5	25
138	Adenoviral Receptor Expression of Normal Bladder and Transitional Cell Carcinoma of the Bladder. Urologia Internationalis, 2007, 78, 160-166.	1.3	24
139	Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. BJU International, 2013, 111, 589-595.	2.5	24
140	ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial Carcinoma of the Prostate. European Urology, 2013, 63, 81-87.	1.9	24
141	The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. World Journal of Urology, 2014, 32, 453-459.	2.2	24
142	Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy. BJU International, 2018, 122, 627-632.	2.5	24
143	Predictors of Benign Ureteroenteric Anastomotic Strictures After Radical Cystectomy and Urinary Diversion. Urology, 2020, 144, 225-229.	1.0	22
144	Update of the ICUDâ€“SIU International Consultation on Bladder Cancer 2018: urinary diversion. World Journal of Urology, 2019, 37, 85-93.	2.2	21

#	Article	IF	Citations
145	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. European Urology, 2020, 78, 907-915.	1.9	21
146	Definition of a Structured Training Curriculum for Robot-assisted Radical Cystectomy with Intracorporeal Ileal Conduit in Male Patients: A Delphi Consensus Study Led by the ERUS Educational Board. European Urology Focus, 2022, 8, 160-164.	3.1	21
147	Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. European Urology Focus, 2019, 5, 365-368.	3.1	20
148	Radical Cystectomy and Lymphadenectomy for Invasive Bladder Cancer: Towards the Evolution of an Optimal Surgical Standard. Seminars in Oncology, 2007, 34, 110-121.	2.2	19
149	Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder. Clinical Genitourinary Cancer, 2018, 16, e23-e27.	1.9	19
150	Utility of Routine Preoperative ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy. Journal of Urology, 2020, 204, 254-259.	0.4	19
151	A Plea for a Uniform Surveillance Schedule After Radical Cystectomy. Journal of Urology, 2011, 185, 2091-2096.	0.4	17
152	Intradiverticular bladder cancer: CT imaging features and their association with clinical outcomes. Clinical Imaging, 2015, 39, 94-98.	1.5	17
153	Optimal timing of radical cystectomy for patients with T1 bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 329-331.	1.6	16
154	Gene therapy in bladder cancer. Current Opinion in Urology, 2008, 18, 519-523.	1.8	15
155	The role of PTEN tumor suppressor pathway staining in carcinoma in situ of the bladder11Funding: Supported by the Sidney Kimmel Center for Prostate and Urologic Cancer and the Michael and Zea Wiener Foundation. Dr Sfakianos is a research fellow in urologic oncology supported by NIH T32-CA82088.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 657-662.	1.6	15
156	Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 603.e1-603.e5.	1.6	15
157	Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapy. BJU International, 2011, 108, E272-E277.	2.5	14
158	Urinary Diversion Practice Patterns Among Certifying American Urologists. Journal of Urology, 2013, 189, 1042-1047.	0.4	14
159	Aminopeptidase activities as prospective urinary biomarkers for bladder cancer. Proteomics - Clinical Applications, 2014, 8, 317-326.	1.6	14
160	Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. British Journal of Cancer, 2021, 124, 1214-1221.	6.4	14
161	Use of nomograms as predictive tools in bladder cancer. World Journal of Urology, 2006, 24, 489-498.	2.2	13
162	Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063). Bladder Cancer, 2017, 3, 113-119.	0.4	13

#	Article	IF	Citations
163	Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis. Cancer, 2018, 124, 2507-2514.	4.1	13
164	Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 213-218.	1.9	13
165	Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience. Journal of Urology, 2020, 204, 677-684.	0.4	13
166	Umbilical Endometriosis. Journal of Urology, 2003, 170, 2388-2389.	0.4	12
167	Use of an ureteroileocecal appendicostomy urinary reservoir in patients with recurrent pelvic malignancies treated with radiation. Gynecologic Oncology, 2004, 94, 140-146.	1.4	12
168	Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience. International Scholarly Research Notices, 2014, 2014, 1-6.	0.9	12
169	Adherence to surveillance guidelines after radical cystectomy: A population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 779-784.	1.6	12
170	Development and validation of surgical training tool: cystectomy assessment and surgical evaluation (CASE) for robot-assisted radical cystectomy for men. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 4458-4464.	2.4	12
171	Current status of establishing standards for lymphadenectomy in the treatment of bladder cancer. Current Opinion in Urology, 2005, 15, 315-319.	1.8	11
172	Ureteroileocecal Appendicostomy Based Urinary Reservoir in Irradiated and Nonirradiated Patients. Journal of Urology, 2009, 182, 2376-2381.	0.4	11
173	Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma. BJU International, 2010, 106, 1502-1507.	2.5	11
174	Quality of life and symptom assessment in randomized clinical trials of bladder cancer: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 331.e17-331.e23.	1.6	11
175	Association Between Urinary Cytology and Pathology for Nontransitional Cell Malignancies of the Urinary Tract. Journal of Urology, 2006, 175, 2038-2041.	0.4	10
176	Bladder cancer imaging. Current Opinion in Urology, 2011, 21, 393-397.	1.8	10
177	The use and abuse of data: Nomograms and talking to patients about clinical medicine. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 333-337.	1.6	9
178	Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy. BJU International, 2022, 129, 463-469.	2.5	9
179	Title is missing!. , 2017, , .		9
180	274: Phase II Trial of Intra Vesical Gemcitabine in BCG-Refractory Transitional Cell Carcinoma of the Bladder. Journal of Urology, 2004, 171, 72-72.	0.4	9

#	Article	IF	Citations
181	Accuracy of Self-reported Smoking Exposure Among Bladder Cancer Patients Undergoing Surveillance at a Tertiary Referral Center. European Urology Focus, 2016, 2, 441-444.	3.1	8
182	Idiographic quality of life assessment before radical cystectomy. Psycho-Oncology, 2017, 26, 206-213.	2.3	8
183	Feasibility of a geriatric comanagement (GERICO) pilot program for patients 75 and older undergoing radical cystectomy. European Journal of Surgical Oncology, 2022, 48, 1427-1432.	1.0	8
184	The effect of age on bladder cancer incidence, prognosis and therapy. Aging Health, 2010, 6, 649-659.	0.3	7
185	Radical Transurethral Resection Alone, Robotic or Partial Cystectomy, or Extended Lymphadenectomy. Urologic Clinics of North America, 2015, 42, 189-199.	1.8	7
186	Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e113-e120.	1.9	7
187	Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy. World Journal of Urology, 2019, 37, 2401-2407.	2.2	7
188	Primary urethral cancer: treatment patterns and associated outcomes. BJU International, 2020, 126, 359-366.	2.5	7
189	Summary of the 6th annual bladder cancer think tank: New directions in urologic research. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 968-973.	1.6	6
190	Does minimally invasive surgery for radical cystectomy provide similar long-term cancer control as open radical surgery?. Current Opinion in Urology, 2013, 23, 449-455.	1.8	6
191	The Outcome of Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Metastatic Bladder Cancer in the Retroperitoneum. Bladder Cancer, 2019, 5, 13-19.	0.4	6
192	Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy. Journal of Urology, 2021, 205, 400-406.	0.4	6
193	Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. JCO Precision Oncology, 2022, , .	3.0	6
194	Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device. Urology, 2018, 122, 121-126.	1.0	5
195	Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. Clinical Genitourinary Cancer, 2022, 20, 431-441.	1.9	5
196	Intravesical bacillus Calmetteâ€“GuÃ©rin combined with electromotive mitomycin for high-risk superficial bladder cancer. Nature Clinical Practice Oncology, 2006, 3, 474-475.	4.3	4
197	More on Robot-Assisted Laparoscopic Radical Cystectomy. New England Journal of Medicine, 2014, 371, 1654-1655.	27.0	4
198	Male Neobladder. Urologic Clinics of North America, 2018, 45, 37-48.	1.8	4

#	Article	IF	Citations
199	Standardizing the care of invasive bladder cancer. Nature Reviews Clinical Oncology, 2011, 8, 454-455.	27.6	3
200	Technical Advances in Bladder Cancer Patient Care: Progress or Promise?. European Urology, 2012, 62, 814-815.	1.9	3
201	Re: Whole-genome and Whole-exome Sequencing of Bladder Cancer Identifies Frequent Alterations in Genes Involved in Sister Chromatid Cohesion and Segregation. European Urology, 2015, 67, 350-351.	1.9	3
202	Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. European Urology, 2020, 77, 1-2.	1.9	3
203	Ureteroâ€enteric stricture outcomes: secondary analysis of a randomised controlled trial comparing open versus robotâ€assisted radical cystectomy. BJU International, 2022, 130, 809-814.	2.5	3
204	AN ALTERNATIVE URETEROILEAL REIMPLANTATION USED IN AUGMENTATION CYSTOPLASTY FOR NEUROGENIC BLADDER WITH BILATERAL VESICOURETERAL REFLUX. Journal of Urology, 1998, 160, 1416-1417.	0.4	2
205	Detection and Management of Isolated Lymph Node Recurrence in Patients with PSA Relapse. European Urology, 2007, 52, 310-312.	1.9	2
206	Does DW-MRI have a role in the evaluation of hematuria?. Nature Reviews Urology, 2009, 6, 469-470.	3.8	2
207	Re: Outcome After Radical Cystectomy with Limited or Extended Pelvic Lymph Node Dissection. European Urology, 2010, 57, 175.	1.9	2
208	Oncologic Outcomes Achieved by Radical Cystectomy. European Urology, 2013, 64, 225-226.	1.9	2
209	Id Proteins Contribute to Tumor Development and Metastatic Colonization inÂa Model of Bladder Carcinogenesis. Bladder Cancer, 2015, 1, 159-170.	0.4	2
210	Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma who have Progressed Following Treatment with Platinum-based Chemotherapy: A Single-arm, Multicenter, Phase 2 Trial. European Urology, 2017, 71, 299-300.	1.9	2
211	Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. World Journal of Urology, 2018, 36, 645-653.	2.2	2
212	Evolution in technique of robotic intracorporeal continent catheterizable pouch after cystectomy. Urology Video Journal, 2019, 4, 100020.	0.2	2
213	Lymph Node Dissection for Advanced Bladder Cancer: Is There a Role?. European Urology Focus, 2020, 6, 615-616.	3.1	2
214	CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. Bladder Cancer, 2021, 7, 1-6.	0.4	2
215	Complications of Ileal Conduit Diversion. , 2017, , 63-79.		2
216	Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations. Journal of Urology, 2020, 204, 460-465.	0.4	2

#	Article	IF	Citations
217	Importance of Node Dissection in Relation to Neoadjuvant and Adjuvant Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 1019-1026.	4.9	1
218	Multimodal therapy for urologic cancers. Nature Reviews Urology, 2006, 3, 453-453.	1.4	1
219	Postchemotherapy Surgery for Advanced Urothelial Cancer: Another Tool To Improve Outcome. European Urology, 2018, 73, 558-559.	1.9	1
220	Reply to Siebren Dijkstra and Carl J. Wijburg's Letter to the Editor re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. Eur Urol 2018;74:465â€“71. Can the Pattern of Cancer Recurrence Truly be Assigned to the Surgical Modality?. European Urology, 2019, 75, e138-e139.	1.9	1
221	Urethral Melanoma â€“ Clinical, Pathological and Molecular Characteristics. Bladder Cancer, 2022, 8, 291-301.	0.4	1
222	NOREPINEPHRINE PRODUCING RENAL CELL CARCINOMA. Journal of Urology, 2001, 166, 603-603.	0.4	0
223	Importance of lymph node dissection in urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 197.	1.6	0
224	Is lymphovascular invasion an important prognostic factor in patients with bladder cancer?. Nature Reviews Urology, 2006, 3, 188-189.	1.4	0
225	How prevalent is neobladder emptying failure, and how can it be treated?. Nature Reviews Urology, 2007, 4, 364-365.	1.4	0
226	Overview of SUO Winter 2008 proceedings. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 67-68.	1.6	0
227	Intravesical Fiducial Marker Placement to Facilitate Image-Guided Radiation Therapy for Patients With Muscle-Invasive Bladder Cancer. UroToday International Journal, 2011, 04, .	0.1	0
228	Re: â€œPelvic exenteration with curative intent for recurrent uterine malignanciesâ€• Gynecologic Oncology, 2012, 126, 312-313.	1.4	0
229	Towards risk stratification in bladder cancer. Nature Reviews Urology, 2013, 10, 374-375.	3.8	0
230	Editorial Comment. Urology, 2014, 83, 861-862.	1.0	0
231	A Thoughtful Pause for Sparing Oophorectomy. Urology, 2019, 129, 237.	1.0	0
232	Expeditious Radical Cystectomy in Patients with High-risk Bladder Cancer Remains an Important Part of Patient Care. European Urology Oncology, 2020, 3, 250-251.	5.4	0
233	AUTHOR REPLY. Urology, 2020, 135, 65.	1.0	0
234	Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016. European Urology, 2021, 79, e56-e57.	1.9	0

#	Article	IF	Citations
235	Management of Common Complications After Radical Cystectomy, Lymph Node Dissection, and Urinary Diversion. , 2021, , 185-203.		0
236	Identification of Nodal Metastases: The role of Iron Oxide Enhanced MRI. , 2009, , 67-77.		0
237	Muscle-Invasive Urothelial Carcinoma: Conventional and Variant Subtypes. , 2012, , 143-163.		0
238	The Role of Lymphadenectomy in the Management of Urothelial Carcinoma of the Upper Urinary Tract. , 2015, , 153-178.		0
239	Reply by Authors. Journal of Urology, 2020, 204, 259-259.	0.4	0
240	Reply by Authors. Journal of Urology, 2020, 204, 684-684.	0.4	0